

17th Vaccine Congress

24–27 September 2023 • Hilton Glasgow, Scotland



Sunday, 24th September 2023

17:00 -
18:30

Registration and Welcome drinks reception

Foyer

Monday, 25th September 2023

09:15 -
11:00

Opening plenary session

Ballroom 1/2

Gregory A. Poland, Claire Cameron

Oral

09:15 - 09:40

Opening remarks

Conference Chair and Local Chair, Gregory A. Poland and Claire Cameron

09:40 - 10:20 [KN01]

2023 Rachael Schneerson - John Robbins Award Lecture: "Running the gauntlet advancing neglected tropical disease vaccines from concept to delivery"

[Maria Elena Bottazzi](#)

Baylor College of Medicine, Houston, TX, USA

10:20 - 11:00 [KN02]

2023 Edward Jenner Vaccine Award Lecture: "The challenges and opportunities for RNA vaccines"

[Robin Shattock](#)

Imperial College London, UK

11:00 -
11:30

Refreshment break

Foyer

11:30 -
13:00

Breakout session 1 - Computational design of new vaccines (AI)

Ballroom 1/2

Albert C. Shaw, Ivan Hung

Oral

11:30 - 12:00 [INV01]

Creating smarter vaccines: Understanding our immune system with artificial intelligence

[Adriana Tomic](#)

Boston University, Boston, MA, USA

12:00 - 12:15 [O1.1]

A bivalent protein vaccine shows potent non-human primate efficacy against Sudan ebolavirus and Marburg marburgvirus as well as significant thermostability for at least two years

[Axel Lehrer](#)¹, Albert To¹, Aquena Ball¹, Teri Ann Wong¹, Michael Lieberman¹, Oreola Donini², Kendall Preston³, Theodore Randolph³, Thomas Geisbert⁴

¹University of Hawai'i at Mānoa, Honolulu, HI, USA. ²Soligenix Inc, Princeton, NJ, USA. ³University of Colorado Boulder, Boulder, CO, USA. ⁴UNIVERSITY OF TEXAS MEDICAL BRANCH, Galveston, TX, USA

12:15 - 12:30 [O1.2]

Using reporter virus particles (RVPs) to characterize the immune response to viruses and vaccines

[Edgar Davidson](#), Chida Sulli, Allison Sheetz, Parul Ganjoo, Lewis J. Stafford
Integral Molecular Inc, Philadelphia, PA, USA

12:30 - 12:45 [O1.3]

Preclinical validation of a computational vaccine design platform that predicts T cell responses with high accuracy

[Eszter Somogyi](#)¹, Mariann Kremlitzka¹, Zsolt Csiszovszki¹, Levente Molnár¹, Orsolya Lőrincz¹, József Tóth¹, Sofie Pattijn², [Enikő Tóke](#)¹

¹Treos Bio Limited, London, UK. ²ImmunXperts (Q2 Solutions), Rotterdam, Belgium

12:45 - 13:00 [O1.4]

Understanding the impact of primary SARS-CoV-2 infection prior to vaccination

Breakout session 2 - Vaccines against STI's

Ballroom 3

Amy Chung, Jen Nelson

Oral

11:30 - 12:00 [INV02]

Evidence for a single dose HPV vaccine regimen

[Deborah Watson-Jones](#)

London School of Hygiene & Tropical Medicine, London, UK. Mwanza Intervention Trials Unit, National Institute for Medical Research, Tanzania, United Republic of

12:00 - 12:15 [O2.1]

HPV antibody profiles 6 years after a single dose of HPV vaccine in adolescent Fijian girls

[Chau Quang](#)^{1,2}, Evelyn Tuivaga³, Tupou Ratu³, Ian Frazer⁴, Suzanne Garland^{5,2,1}, Fiona Russell^{1,2}, Bruce Wines^{6,7,8}, Mark Hogarth^{6,7,8}, Kim Mulholland^{1,9,10}, Amy Chung^{8,11}, Paul Licciardi^{1,2}, Zheng Quan Toh^{1,2}

¹Murdoch Children's Research Institute, Parkville, Australia. ²The University of Melbourne, Parkville, Australia. ³Republic of Fiji Ministry of Health, Suva, Fiji.

⁴The University of Queensland Diamantina Institute, Woolloongabba, Australia.

⁵The Royal Women's Hospital, Australia. ⁶Burnet Institute, Melbourne, Australia.

⁷Monash University, Melbourne, Australia. ⁸The University of Melbourne, Melbourne, Australia. ⁹London School of Hygiene & Tropical Medicine, London, UK. ¹⁰Menzies School of Health Research, Casuarina, Australia. ¹¹The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

¹²The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

¹³The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

¹⁴The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

¹⁵The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

¹⁶The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

¹⁷The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

¹⁸The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

¹⁹The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²⁰The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²¹The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²²The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²³The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²⁴The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²⁵The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²⁶The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²⁷The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²⁸The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

²⁹The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

³⁰The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

Ash Otter, Hannah White, Hannah Selman, Sarah Foulkes, Edward Monk, Bethany Hicks, Ellie Cross, Georgia Hemingway, Amanda Semper, Susan Hopkins, Victoria Hall, Tim Brooks
UK Health Security Agency, London, UK

targeting strategies and dosing schedules, and the importance of behavioural science in understanding vaccine sentiment

Dariya Nikitin¹, Lilith Whittles¹, Jeffrey Eaton^{1,2}, Peter White¹

¹Imperial College, London, UK. ²Harvard University, Boston, MA, USA

12:45 - 13:00 [O2.4]

Routine health behaviors and HPV vaccine uptake in a sample of women living in the Appalachian region of the United States

Chesney Ward, Ishita Kapur, Melody Huslage, William Nugent, Gretchen Ely
The University of Tennessee System, Knoxville, TN, USA

13:00 -
14:00

Lunch

Foyer

14:00 -
15:30

Breakout session 3 - Vaccine mandates

Ballroom 1/2

Carlos Del Rio, Lee H. Harrison

Oral

14:00 - 14:30 [INV03]

Confronting legal backlash against COVID-19 vaccine mandates

Lawrence Gostin

Georgetown University, Washington, DC, USA

14:30 - 14:45 [O3.1]

Facilitating pathways to vaccination in rural and tribal populations of India

Rajni Wadhwa¹, Gopal Krishna Soni², Ashok Raisinghani², Sourav Dastidar²,

Vijay Paulraj³, Tushar Kanti Das¹, Mohammed Asif¹

¹Plan International (India Chapter), New Delhi, India. ²John Snow India Private Limited, India. ³USAID India, New Delhi, India

14:45 - 15:00 [O3.2]

Training of service providers for pneumococcal conjugate vaccine

introduction in India: Results of national level pre and post test evaluation

Jayanta Majumder¹, Arindam Ray², Rashmi Mehra¹, Amrita Kumari¹, Amanjot

Kaur¹, Semma Singh Koshal¹, Rhythm Hora¹, Syed F. Quadri¹, Pradeep Halder¹,

Arup Deb Roy¹

¹John Snow Inc India, New Delhi, India. ²Bill & Melinda Gates Foundation India, New Delhi, India

15:00 - 15:15 [O3.3]

Process documentation of post introduction evaluation of rotavirus vaccine in India

Amrita Kumari¹, Arindam Ray², Rhythm Hora¹, Amanjot Kaur¹, Rashmi Mehra¹,

Seema Singh Koshal¹, Syed F Quadri¹, Pradeep Halder¹, Arup Deb Roy¹

¹John Snow Inc India, New Delhi, India. ²Bill & Melinda Gates Foundation India, New Delhi, India

15:15 - 15:30 [O3.4]

Wristband for immunization alert: A Game-changer for improving routine immunization timeliness among caregivers in Kano state

Sidney Sampson, Adebisi Adenipekun, Sunday Atobatele, Oluwafisayo Ayodeji,

Oluomachukwu Omeje, Folake Oni

Sydani Group, Nigeria

Breakout session 4 - Immunisation and special populations

Ballroom 3

Claire Cameron, Carl Goodyear

Oral

14:00 - 14:30 [INV04]

SARS-CoV-2 vaccine responses in individuals with immuno-suppressive disease

Carl Goodyear

University of Glasgow, UK

14:30 - 14:45 [O4.1]

The use of a prioritisation matrix to address ethnic inequalities in immunisation uptake in new Zealand

Owen Sinclair

Te Whatu Ora Waitemata, New Zealand. New Zealand Ministry of Health, Wellington, New Zealand. The University of Auckland, Auckland, New Zealand. Paediatric Society of New Zealand, New Zealand

14:45 - 15:00 [O4.2]

Patterns of T cell response to SARS-CoV-2 vaccination in children and adults with cancer

Amy Body^{1,2}, Elizabeth Ahern^{1,2}, Katie Lineburg³, Corey Smith³, Luxi Lal¹,

Stephen Opat^{1,2}, C. Raina MacIntyre⁴, Michael F. Leahy⁵, Nada Hamad⁶, Peter

Downie¹, Noemi Fuentes Bolanos⁷, Antoinette Anazodo⁷, Bhavna Padhye⁸,

Sriganesh Srihari³, Eva Segelov²

¹Monash Health, Clayton, Australia. ²Monash University, Clayton, Australia.

³QIMR Berghofer Medical Research Institute, Herston, Australia. ⁴The Kirby

Institute, Kensington, Australia. ⁵Royal Perth Hospital, Perth, Australia. ⁶St

Vincent's Hospital Sydney, Darlinghurst, Australia. ⁷Sydney Children's Hospital

Randwick, Randwick, Australia. ⁸Children's Hospital at Westmead, Westmead,

Australia

15:00 - 15:15 [O4.3]

Exploring how people who are in prison make decisions about vaccines

Lynne Rush, Claire Cameron, Ruth Dryden

Public Health Scotland Glasgow Office, Glasgow, UK

15:15 - 15:30 [O4.4]

Precarity, agency and trust: vaccination decision-making in the context of the UK asylum system

Anna Deal^{1,2}, Maha Salloum^{1,3}, Sally E Hayward^{1,2}, Alison F Crawshaw¹, Jessica

Carter¹, Sandra Mounier-Jack², Sally Hargreaves¹

¹St George's University of London, London, UK. ²London School of Hygiene and

Tropical Medicine, London, UK. ³University of Antwerp, Antwerpen, Belgium

15:30 -
16:00

Refreshment break

Foyer

16:00 -
17:30

Breakout session 5 - Socio political implications of vaccination and vaccine policy

Ballroom 1/2

Gregory A. Poland

Oral

16:00 - 16:30 [INV05]

Trust and science: Public health's home field advantage in addressing vaccine hesitancy and improving immunization rates

Peter Pitts

Center for Medicine in the Public Interest, New York, NY, USA

16:30 - 16:45 [O5.1]

The social life of vaccination: How biographies of caregivers and vaccines interact in shaping willingness to vaccinate small children in the Philippines

Breakout session 6 - Veterinary vaccines

Ballroom 3

Maria Elena Bottazzi, Angela Rasmussen

Oral

16:00 - 16:30 [INV06]

New and emerging viruses in the veterinary field

Wim van der Poel

Wageningen University & Research, Wageningen, The Netherlands

16:30 - 16:45 [O6.1]

The live attenuated BacAA oral vaccine stimulates interferon gamma

production by T cells and provides some protection against intestinal

Mycobacterium paratuberculosis infection in young calves

Razieh Eshraghisamani¹, Antonio Facciolo^{2,3}, Victoria Harman-Mckenna¹,

Zhuohan Miao¹, Ana Hernandez Reyes¹, Jeroen De Buck¹

Jonas Wachinger¹, Mark Donald C. Reñosa^{2,3}, Jhoys Landicho-Guevarra³, Vivienne Endoma³, Shannon A McMahon^{1,4}
¹Heidelberg University, Heidelberg, Germany. ²Heidelberg University, Germany. ³Research Institute for Tropical Medicine, Muntinlupa, The Philippines. ⁴Johns Hopkins University, Baltimore, MD, USA

16:45 - 17:00 [O5.2]

Vaccination choices and stigma among vaccine inquirers in Sweden: A qualitative study

Sibylle Herzig van Wees, Maria Ström
Karolinska Institute, Stockholm, Sweden

17:00 - 17:15 [O5.3]

The Adult Immunization Board: A new platform to provide multidisciplinary guidelines for the implementation and optimization of adult immunization in Europe

Jade Pattyn¹, Marco Del Riccio², Greet Hendrickx¹, Sara Boccacini³, Angela Bechini², Pierre Van Damme¹, Paolo Bonanni²

¹University of Antwerp, Belgium. ²University of Florence, Firenze, Italy.

³University of Florence, Italy

17:15 - 17:30 [O5.4]

Vaccine hesitancy and racial discrimination among US adults

Pearl A. McElfish¹, Don E. Willis¹, Brooke E.E. Montgomery², James P. Selig², Jennifer A. Andersen¹, Sumit K. Shah³, Ji Li², Reece Sharon¹, Derek Alik¹

¹University of Arkansas for Medical Sciences Northwest, Fayetteville, AR, USA.

²University of Arkansas for Medical Sciences Fay W Boozman College of Public Health, Little Rock, AR, USA. ³University of Arkansas for Medical Sciences Northwest, USA

¹University of Calgary, Calgary, AB, Canada. ²Vaccine and Infectious Disease Organization International Vaccine Centre, Saskatoon, SK, Canada. ³University of Saskatchewan, Saskatoon, SK, Canada

16:45 - 17:00 [O6.2]

Maternal vaccine history effects offspring immune response to bovine respiratory vaccine

Cassidy Reddout¹, Christopher Chase², Paul Beck¹, Janeen Salak-Johnson¹

¹Oklahoma State University, Stillwater, OK, USA. ²South Dakota State University, Brookings, SD, USA

17:00 - 17:15 [O6.3]

Insights on the use of the extremely attenuated variant of Rift Valley fever virus (RVFV) 40Fp8 as a safer live-attenuated vaccine

Belen Borrego¹, Enrique Ezcurra¹, Ricardo Martin-Vidal^{1,2}, Raquel de Evan¹, Celia Alonso¹, Gema Lorenzo¹, Alejandro Brun¹

¹Animal Health Research Center, Valdeolmos, Spain. ²Free University of Berlin, Berlin, Germany

17:15 - 17:30 [O6.4]

Tick salivary serpins in the parasite-host relationship

Pedro Albuquerque¹, Lucas Tirloni², Itabajara da Silva Vaz Jr³

¹Universidade Federal do Rio Grande do Sul, PORTO ALEGRE, Brazil. ²National Institute of Allergy and Infectious Diseases, USA. ³Universidade Federal do Rio Grande do Sul, Brazil

17:30 - 19:00

Drinks reception, Poster session 1 & Meet the Editors of journal Vaccine and Vaccine X

Riverside Suites and Foyer
Poster

Tuesday, 26th September 2023

08:30 - 09:00

Researcher academy – Author workshop

Ballroom 3
Dior Beerens
Oral
Fundamentals of peer review

Dior Beerens, Elsevier, Netherlands

09:00 - 11:00

Plenary session 2 - Influenza

Ballroom 1/2
Ivan Hung, Florian Krammer
Oral

09:00 - 09:20 [KN03]

Adjuvants for intradermal vaccines

Kelvin To

The University of Hong Kong, Hong Kong, Hong Kong

09:20 - 09:40 [KN04]

Development of neuraminidase-based broadly protective influenza virus vaccines

Florian Krammer

Icahn School of Medicine at Mount Sinai Department of Microbiology, New York, NY, USA

09:40 - 10:00 [KN05]

Discovery and development of next generation adjuvant systems for more effective vaccines

David Burkhart^{1,2}, Karthik Siram², Hardik Amin², Kristopher Short², Roman Schoener¹, Shannon Miller¹, Jay Evans², Irene Hoxie³, Florian Krammer³

¹Inimmune Corp, USA. ²University of Montana, Missoula, MT, USA. ³Icahn School of Medicine at Mount Sinai, New York, NY, USA

10:00 - 10:15 [OP2.1]

Tools for analyzing the immune response to influenza virus infection and vaccines

Edgar Davidson¹, Lewis J. Stafford¹, Chida Sulli¹, Kelly Dew-Budd¹, Trevor E. Esilu¹, Walter Hardy¹, Rachael Wolters², James E. Crowe Jr²

¹Integral Molecular Inc, Philadelphia, PA, USA. ²Vanderbilt University, Nashville, TN, USA

10:15 - 10:30 [OP2.2]

Genetically engineered defective interfering particles of influenza A virus for application as vaccine and antiviral

Tanya Dogra¹, Lars Pelz¹, Marc Hein², Daniel Ruediger¹, Julia Boehme^{2,3}, Maïke Baelkner³, Pavel Marichal-Gallardo¹, Yvonne Genzel¹, Dunja bruder³, Sascha Young Kupke¹, Udo Reich^{1,2}

¹Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany. ²Otto von Guericke University, Magdeburg, Germany. ³Helmholtz Centre for Infection Research, Braunschweig, Germany

10:30 - 11:00

Panel discussion on Influenza and next steps

11:00 - 11:30	Refreshment break Riverside Suites and Foyer	
11:30 - 13:00	Breakout session 7 - Vaccine durability Ballroom 1/2 Albert C. Shaw, Rick Kennedy Oral 11:30 - 12:00 [INV07] Mumps: Humoral immunity to vaccination and infection <u>Jaythoon Hassan</u> <i>University College Dublin National Virus Reference Laboratory, Dublin, Ireland</i> 12:00 - 12:15 [O7.1] Durability and cross-neutralization of antibody responses induced by COVID-19 vaccination Annika Rössler ¹ , Antonia Netzl ² , Ludwig Knabl ³ , Dorothee von Laer ¹ , Derek J. Smith ² , <u>Janine Kimpel</u> ¹ ¹ Medical University of Innsbruck, Austria. ² University of Cambridge, UK. ³ Tyrolpath Obrist Brunhuber GmbH, Austria 12:15 - 12:30 [O7.2] Evaluation of waning of SARS-CoV-2 vaccine-induced immunity <u>Francesco Menegale</u> ^{1,2} , Mattia Manica ¹ , Agnese Zardini ¹ , Giorgio Guzzetta ¹ , Valentina Marziano ¹ , Valeria d'Andrea ¹ , Filippo Trentini ^{1,3} , Marco Ajelli ⁴ , Piero Poletti ¹ , Stefano Merler ¹ ¹ Bruno Kessler Foundation, Trento, Italy. ² University of Trento, Povo, Italy. ³ Bocconi University, Milano, Italy. ⁴ Indiana University, Bloomington, IN, USA 12:30 - 12:45 [O7.3] Persistence of poliovirus antibodies following primary series before and after a 5th IPV booster dose at school-entry age in Hong Kong <u>Tiffany HK Lo</u> ^{1,2} , Eric HY Lau ^{1,2} , Kathy SM Leung ^{1,2,3} , Joseph TK Wu ^{1,2,3} , Juan C Vargas-Zambrano ⁴ , Celine Petit ⁵ , Tommy TY Lam ^{1,2} , Gabriel M Leung ^{1,2,3} ¹ Laboratory of Data Discovery for Health Limited, Hong Kong. ² The University of Hong Kong, Hong Kong. ³ The University of Hong Kong – Shenzhen Hospital, Shenzhen, China. ⁴ Global Medical Affairs, Sanofi, Lyon, France. ⁵ Global Clinical Immunology, Sanofi, Marcy-l'Etoile, France 12:45 - 13:00 [O7.4] Ebola virus booster vaccinations induce high immune memory responses in healthcare providers and frontliners of the Democratic Republic of the Congo: an open-label, randomised, phase 2 trial <u>Ynke Larivière</u> ¹ , Trésor Zola Matuvanga ^{2,1} , Bernard Osang'ir ¹ , Solange Milolo ² , Rachel Meta ² , Primo Kimbulu ² , Cynthia Robinson ³ , Michael Katwere ³ , Chelsea McLean ³ , Junior Matangila ² , Vivi Maketa ² , Patrick Mitashi ² , Jean-Pierre Van geertruyden ¹ , Pierre Van Damme ¹ , Hypolite Muhindo-Mavoko ² ¹ University of Antwerp, Antwerpen, Belgium. ² University of Kinshasa, Kinshasa, Democratic Republic of Congo. ³ Janssen Vaccines and Prevention BV, Leiden, The Netherlands	Breakout session 8 - Maternal immunization Ballroom 3 Helena Maltezou, Flor Munoz-Rivas Oral 11:30 - 12:00 [INV08] Maternal Immunisation- the in's and out's and discussion points <u>Beate Kampmann</u> <i>Charite University Hospital Berlin, Berlin, Germany. London School of Hygiene & Tropical Medicine, UK</i> 12:00 - 12:30 [INV09] From the very first breath: Realizing the promise of maternal vaccination for the protection of newborns <u>Annaliesa Anderson</u> <i>Pfizer Inc, New York, NY, USA</i> 12:30 - 12:45 [O8.1] Maternal immunization and blunting of pertussis vaccines in infants: Too early to tell <u>Michael Briga</u> ¹ , Elizabeth Goult ¹ , Andrew Tredennick ² , Tobias Brett ² , Pejman Rohani ² , Matthieu Domenech de Celles ¹ ¹ Max-Planck-Institute for Infection Biology, Berlin, Germany. ² University of Georgia, Athens, GA, USA 12:45 - 13:00 [O8.2] Maternal immunisation for the developing world: analysis using an equity approach to opportunities and challenges in Pakistan <u>Mohammad Khan</u> , Dilbar Khan, Noor Sabah Rakhshani <i>PHC Global, Pakistan</i>
13:00 - 14:00	Lunch Foyer	
14:00 - 15:30	Breakout session 9 - Vaccine hesitancy Ballroom 1/2 Gregory A. Poland, Carlos Del Rio Oral 14:00 - 14:30 [INV10] Building engagement and confidence around COVID-19 vaccines <u>Jennie Evans</u> , Erika Aquino <i>British Society for Immunology, London, UK</i> 14:30 - 14:45 [O9.1] The silent shot: An analysis of the origin, sustenance and implications of the measles mumps rubella (MMR) vaccine – autism spectrum disorder (ASD) rumour in the Somali diaspora in Sweden and beyond <u>Sibylle Herzig van Wees</u> <i>Karolinska Institute, Stockholm, Sweden</i> 14:45 - 15:00 [O9.2] The effects of neighborhood socioeconomic deprivation on COVID-19 vaccination reception and hesitancy <u>Mohamed Elsaid</u> ¹ , Chloe Hery ¹ , Xiaochen Zhang ² , Cecilia DeGraffinreid ¹ , Electra Paskett ^{3,4} ¹ The Ohio State University, USA. ² Fred Hutchinson Cancer Research Center Cancer Prevention Program, Seattle, WA, USA. ³ Division of Cancer Prevention	Breakout session 10 - Vaccines for neglected diseases Ballroom 3 Maria Elena Bottazzi, Angela Rasmussen Oral 14:00 - 14:30 [INV11] Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine <u>Maria Elena Bottazzi</u> , Kathryn Jones, Cristina Poveda, Leroy Versteeg, Peter Hotez <i>Baylor College of Medicine, Houston, TX, USA</i> 14:30 - 14:45 [O10.1] Identification of human monoclonal antibodies against Shigella (ShimAbs) for vaccine acceleration <u>Giacomo Vezzan</u> ¹ , Elena Boero ¹ , Assia Duatti ¹ , Maria Michelina Raso ¹ , Giampiero Batani ² , Emanuele Roscioli ² , Matteo Ridelfi ² , Simona Tavarini ³ , Chiara Sammicheli ³ , Carlo Giannelli ¹ , Gianmarco Gasperini ¹ , Francesco Berlanda Scorza ¹ , Mariagrazia Pizza ⁴ , Miren Itturiza ¹ , Omar Rossi ¹ , Claudia Sala ² , Francesca Micoli ¹ , Rino Rappuoli ⁵ ¹ GSK Vaccines Institute for Global Health, Siena, Italy. ² Toscana Life Sciences Foundation, Siena, Italy. ³ GSK Vaccines SRL, Siena, Italy. ⁴ Imperial College London, London, UK. ⁵ Fondazione Biotechnopolo di Siena, Siena, Italy 14:45 - 15:00 [O10.2]

and Control, USA. ⁴Cancer Control Continuum in Ohio and Indiana Consortium, USA

15:00 - 15:15 [O9.3]

Variance in COVID-19 vaccine uptake in at-risk groups in Scotland

Kirsty Morrison, Vera Chua, Lucy Cullen, Allan James, Emmanuel Ezeoke, Christopher Sullivan, Ross McQueenie
Public Health Scotland Glasgow Office, Glasgow, UK

15:15 - 15:30 [O9.4]

Comparing adverse events following COVID-19 viral-vector and mRNA vaccination in Korea: A target trial emulation using real-world data

Keun-Young Yoo^{1,2}, Jaehun Jung^{3,4}, Yewon Na³
¹Veterans Health Service Medical Center, Republic of Korea. ²Seoul National University College of Medicine, Seoul, Republic of Korea. ³Gachon University, Republic of Korea. ⁴Gachon University Gil Medical Center, Incheon, Republic of Korea

Identification and efficacy evaluation of novel antigen candidates against Pseudomonas aeruginosa infections

Irene Jurado Martin¹, Maite Sainz Mejias¹, Yueran Hou¹, John Baugh¹, Juan Anguita², Siobhán McClean¹

¹University College Dublin, Dublin, Ireland. ²Center for Cooperative Research in Biosciences, Derio, Spain

15:00 - 15:15 [O10.3]

Potentials of the chimeric protein consisting of food digestion-involving proteins from Fasciola gigantica to be a protein candidate for vaccine against fasciolosis

Werachon Cheukamud, Supanan Chansap, Narin Changklungmoa, Pornanan Kueakhai
Burapha University, Thailand

15:15 - 15:30 [O10.4]

Advancement of lepVax, a leprosy vaccine with therapeutic and prophylactic potential

Becky Rivoire¹, Veronica Schmitz², Malcolm Duthie³, Stefanie Weiland¹
¹American Leprosy Missions, USA. ²Fundação Oswaldo Cruz, Brazil. ³Consultant, USA

15:30 -
17:00

Refreshment break & Poster session 2

Riverside Suites and Foyer
Poster

17:00 -
18:30

Breakout session 11 - Roundtable – 3rd Generation Covid vaccines – State of the art lecture and discussion on immunology

Ballroom 1/2
Gregory A. Poland, Amy Chung
Oral

17:00 - 17:20 [LEC1]

COVID-19 Vaccines: What do we have and what do we need?

Rick Kennedy
Mayo Clinic, USA

17:20 - 17:40 [LEC2]

Correlates of protection for COVID-19 vaccines

Dan Barouch
Harvard University, USA

17:40 - 18:00 [LEC3]

Next-generation pan-sarbecovirus vaccine: a live-attenuated nasal spray vaccine comprised of an Interferon-Beta Integrated SARS-CoV-2

Chun-Kit Yuen^{1,2}, Wan-Man Wong^{1,2}, Long-Fung Mak^{1,2}, Kwok-Yung Yuen^{1,2}, Kin-Hang Kok^{3,2}
¹Department of Microbiology, The University of Hong Kong, Hong Kong. ²Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong. ³Department of Microbiology, The University of Hong Kong, Hong Kong, Hong Kong

18:00 - 18:30 Discussion

19:30 -
22:00

Conference dinner (ticketed)

Glasgow City Chambers
Dinner speaker from Jenner Museum - Gareth Williams, Jenner Society, UK

Talk title: Edward Jenner: a man who changed the face of the world

Wednesday, 27th September 2023

08:00 -
09:00

Expert roundtable: Rebuilding vaccine confidence in the post-pandemic world

Ballroom 3
Scott Ratzan
Oral
Chairman's introduction - an appraisal - there's more to be done

Scott Ratzan, MD Journal of Health Communication, CUNY School of Public Health and Business Partners to CONVINCING "Hesitancy Now"

Vaccine Confidence Project global update

Ana Bolio-Ruiz, Vaccine Confidence Project, LSH&TM

New findings, highlights of a recent survey in seven major vaccine markets

Jia Hu, 19 To Zero, University of Calgary, Canada

From hesitance to confidence and trust - The big questions

Ken Rabin, Journal of Health Communication, CUNY School of Public Health

09:00 -
11:00

Plenary session 3 - RSV

Ballroom 1/2
Gregory A. Poland, Flor Munoz-Rivas
Oral

09:00 - 09:30 [KN06]

Preventing RSV in infants and young children: Challenges and updates for 2023

Asuncion Meijas
St. Jude Children's Research Hospital, Memphis, TN, USA

09:30 - 10:00 [KN07]

RSV prevention in adults: Progress, pitfalls and future directions

Angela Branche
University of Rochester, Rochester, NY, USA

10:00 - 10:30 [KN08]

Weighing the RSV data - What should clinicians do?

Flor Munoz-Rivas
Baylor College of Medicine, USA

10:30 - 10:45 [OP3.1]

Prevalence of RSV among acute lower respiratory tract disease (aLRTD) hospitalizations and projected seasonal RSV-related aLRTD hospitalization incidence among adults in bristol uk – 2022–2023

David Adegbite¹, Elizabeth Begier², Jade King³, Jo Southern², Serena McGuinness¹, Robin Hubler², Jennifer Oliver¹, Andrew Vyse², Negar Aliabadi², Bradford Gessner², Adam Finn¹, Catherine Hyams¹
¹University of Bristol, Bristol, UK. ²Pfizer Inc Pennsylvania, Collegeville, PA, USA. ³North Bristol NHS Trust, Bristol, UK

10:45 - 11:00 [OP3.2]

Cost-effectiveness of monoclonal antibodies and maternal vaccine programmes against RSV

David Hodgson¹, Stefan Flasche¹, Mark Jit¹, Katherine Atkins^{1,2}
¹London School of Hygiene & Tropical Medicine, London, UK. ²The University of Edinburgh, Edinburgh, UK

11:00 -
11:30

Refreshment break

Riverside Suites and Foyer

11:30 -
13:00

Breakout session 12 - Hot topics

Ballroom 1/2
Rick Kennedy, Florian Krammer
Oral

11:30 - 12:00 [INV12]

Sex differences in immunity to vaccines across the life course

Inna Ovsyannikova, Richard Kennedy, Gregory Poland
Mayo Clinic Minnesota, Rochester, MN, USA

12:00 - 12:15 [O12.1]

Bordetella pertussis clinical isolates express novel high-affinity antigens presented on MHC Class II that elicit T-cell responses *in vivo*

Mohamed Shamseldin¹, Jesse Hall¹, Gabrielle Hernandez², Eva Verzani², Steven Carr², Rajendar Deora¹, Jenn Abelin², Purnima Dubey¹
¹The Ohio State University, Columbus, OH, USA. ²Broad Institute, Cambridge, MA, USA

12:15 - 12:30 [O12.2]

Analogous humoral antigen recognition between Smallpox-vaccinated and Mpox-infected individuals

Ash Otter¹, Scott Jones², Bethany Hicks², Daniel Bailey², Helen Callaby², Catherine Houlihan², Claire Gordon², Tim Brooks², Richard Vipond², Cathy Rowe², Bassam Hallis²
¹UK Health Security Agency, UK. ²UK Health Security Agency, London, UK

12:30 - 12:45 [O12.3]

Antibody correlates of protection against Delta infection after vaccination: a nested case-control within the UK-based SIREN study

Ana Atti¹, Ferdinando Insalata¹, Edward Carr², Ashley Otter³, Sarah Foulkes¹, Mary Wu², Michelle Cole¹, Ezra Linley⁴, Amanda Semper³, Tim Brooks³, Susan Hopkins¹, Andre Charlett¹, Rupert Beale², Victoria Hall¹
¹UK Health Security Agency, London, UK. ²The Francis Crick Institute, London, UK. ³Service UK Health Security Agency - Porton, Salisbury, UK. ⁴UK Health Security Agency North West, Manchester, UK

12:45 - 13:00 [O12.4]

Exploiting real-time genomic surveillance data to assess 4CMenB meningococcal vaccine performance in Scotland 2015-2022

Charlene Rodrigues^{1,2,3}, Laura MacDonald⁴, Roisin Ure⁵, Martin Maiden¹, Andrew Smith⁵, Claire Cameron⁴
¹University of Oxford, Oxford, UK. ²London School of Hygiene & Tropical Medicine, London, UK. ³Imperial College Healthcare NHS Trust, London, UK.

Breakout session 13 - One Health in Complex Settings (OHICS)/ Fragile environments

Ballroom 3
Lee H. Harrison, Angela Rasmussen
Oral

11:30 - 12:00 [INV13]

Looking into the evolution of bat coronaviruses to understand the future of SARS-CoV-2

Spyros Lytras
MRC-University of Glasgow Centre for Virus Research, UK

12:00 - 12:30 [INV14]

Potential animal reservoirs for SARS-CoV-2 at the zoonanthropotic interface

Angela Rasmussen
Vaccine and Infectious Disease Organization International Vaccine Centre, Saskatoon, SK, Canada

12:30 - 12:45 [O13.1]

Utilizing reverse vaccinology to identify antigenic epitopes across poultry-relevant serovars for development of a multiepitope, cross-protective *Salmonella* vaccine

David Bradshaw^{1,2}, Shawn Bearson¹
¹USDA-ARS National Animal Disease Center, Ames, IA, USA. ²Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA

⁴Public Health Scotland Glasgow Office, Glasgow, UK. ⁵Bacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, UK

13:00 -
14:00

Spotlight on Scotland and the UK

Ballroom 1/2

Oral

Claire Cameron, Public Health Scotland, UK

Daniel Chandler, Associate Director of Public Health / Immunisation Coordinator NHS Tayside, UK

Mary Ramsay, Director of Public Health Programmes in the UK Health Security Agency, UK

Chris Johnson, Public Health Wales, UK

Jason Leitch, National Clinical Director, Scotland

14:00 -
14:10

Closing remarks

Ballroom 1/2

Gregory A. Poland, Claire Cameron

Oral